Table 3. Univariate analysis of baseline predictors of survival.
| Variable | Median survival (months) | P value | |
| Age | <56 | 15 | 0.24 |
| ≥56 | 16 | ||
| Sex | Male | 15 | 0.09 |
| Female | 17 | ||
| Ascites | Absent | 20 | <0.001 |
| Present | 8 | ||
| Number of tumor nodule | One | 20 | <0.001 |
| Two | 16 | ||
| Three | 11 | ||
| Multiple | 8 | ||
| Maximum tumor diameter | ≤5 cm | 26 | <0.001 |
| >5 cm | 12 | ||
| PVT | Absent | 19 | <0.001 |
| Present | 6 | ||
| Extrahepatic metastasis | Absent | 16 | <0.001 |
| Present | 6 | ||
| AFP level | <200 | 20 | <0.001 |
| ≥200 | 11 | ||
| Child-Pugh score | A | 30 | <0.001 |
| B | 15 | ||
| C | 5 | ||
| Treatment modality | Resection | 36 | <0.001 |
| Transplantation | 12 | ||
| PEI | 20 | ||
| RFA | Undefined | ||
| TACE | 18 | ||
| Microwave ablation | Undefined | ||
| Sorafenib | 7 | ||
| Supportive | 6 |
P value <0.05 is significant.